Abstract
Sodium valproate (VA) and clonazepam (CLZ) were combined in the treatment of 4 patients with panic disorders (PD) who were resistant to several antipanic drug treatments. A significant improvement was found in the symptomatology of these patients, but relapses occurred when CLZ dosage was reduced. A potentiation of the GABAergic properties of VA and clonazepam is postulated. This combined treatment could be advantageous for some treatment-resistant PD patients but needs to be studied further.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Fowler L. J., Beckford J., John R. A. An analysis of the kinetics of the inhibition of rabbit brain gamma-aminobutyrate aminotransferase by sodium n-dipropylacetate and some other simple carboxylic acids. Biochem Pharmacol. 1975 Jul 15;24(13-14):1267–1270. doi: 10.1016/0006-2952(75)90334-2. [DOI] [PubMed] [Google Scholar]
- Gram L., Bentsen K. D. Valproate: an updated review. Acta Neurol Scand. 1985 Aug;72(2):129–139. doi: 10.1111/j.1600-0404.1985.tb00854.x. [DOI] [PubMed] [Google Scholar]
- Levin A. P., Liebowitz M. R. Drug treatment of phobias. Efficacy and optimum use. Drugs. 1987 Oct;34(4):504–514. doi: 10.2165/00003495-198734040-00004. [DOI] [PubMed] [Google Scholar]
- Löscher W., Frey H. H. Effect of convulsant and anticonvulsant agents on level and metabolism of gamma-aminobutyric acid in mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1977 Feb;296(3):263–269. doi: 10.1007/BF00498692. [DOI] [PubMed] [Google Scholar]
- Macdonald R. L., Bergey G. K. Valproic acid augments GABA-mediated postsynaptic inhibition in cultured mammalian neurons. Brain Res. 1979 Jul 20;170(3):558–562. doi: 10.1016/0006-8993(79)90975-2. [DOI] [PubMed] [Google Scholar]
- Naylor G. J., Smith A. H., Connelly P. Methylene blue in mania. Biol Psychiatry. 1988 Dec;24(8):941–942. doi: 10.1016/0006-3223(88)90229-6. [DOI] [PubMed] [Google Scholar]
- Noyes R., Jr, DuPont R. L., Jr, Pecknold J. C., Rifkin A., Rubin R. T., Swinson R. P., Ballenger J. C., Burrows G. D. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. Arch Gen Psychiatry. 1988 May;45(5):423–428. doi: 10.1001/archpsyc.1988.01800290037005. [DOI] [PubMed] [Google Scholar]
- Noyes R., Jr, Garvey M. J., Cook B. L., Samuelson L. Problems with tricyclic antidepressant use in patients with panic disorder or agoraphobia: results of a naturalistic follow-up study. J Clin Psychiatry. 1989 May;50(5):163–169. [PubMed] [Google Scholar]
- Noyes R., Jr, Reich J., Christiansen J., Suelzer M., Pfohl B., Coryell W. A. Outcome of panic disorder. Relationship to diagnostic subtypes and comorbidity. Arch Gen Psychiatry. 1990 Sep;47(9):809–818. doi: 10.1001/archpsyc.1990.01810210017003. [DOI] [PubMed] [Google Scholar]
- Primeau F., Fontaine R., Beauclair L. Valproic acid and panic disorder. Can J Psychiatry. 1990 Apr;35(3):248–250. doi: 10.1177/070674379003500309. [DOI] [PubMed] [Google Scholar]
- Ticku M. K., Davis W. C. Effect of valproic acid on [3H]diazepam and [3H]dihydropicrotoxinin binding sites at the benzodiazepine-GABA receptor-ionophore complex. Brain Res. 1981 Oct 26;223(1):218–222. doi: 10.1016/0006-8993(81)90828-3. [DOI] [PubMed] [Google Scholar]
- Zitrin C. M., Klein D. F., Woerner M. G., Ross D. C. Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry. 1983 Feb;40(2):125–138. doi: 10.1001/archpsyc.1983.01790020019002. [DOI] [PubMed] [Google Scholar]